ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ º¸Á¶Ç×¾ÏÈÇпä¹ý
Adjuvant Chemotherapy in Non-Small Cell Lung Cancer
´ëÇѳ»°úÇÐȸÁö 2012³â 83±Ç 3È£ p.305 ~ p.308
±èµ¿¿Ï(Kim Dong-Wan) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Complete surgical resection is a potentially curable treatment for localized non-small cell lung cancer. However, unfortunately, a significant proportion of patients experience recurrence after curative intent operation. To reduce the rate of recurrence after surgery, adjuvant chemotherapy has been studied in a series of randomized trials. The aim of the present review is to summarize the expected survival benefit of adjuvant chemotherapy and to define the adequate target population of adjuvant treatment based on the results from large randomized trials.
Å°¿öµå
º¸Á¶Ç×¾ÏÈÇпä¹ý, ºñ¼Ò¼¼Æ÷Æó¾Ï, ½Ã½ºÇöóƾ
Adjuvant chemotherapy, Non-small cell lung cancer, Cisplatin
KMID :
0882420120830030305
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
¼ö¼ú·Î ÀýÁ¦µÈ ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚ¿¡¼ cisplatin ±â¹Ý º¸Á¶Ç×¾ÏÈÇпä¹ýÀº »ýÁ¸À²À» Çâ»ó½ÃÅ°¸ç ±× È¿°ú´Â stage II, IIIA ȯÀÚ¿¡¼ ¸íÈ®ÇÏ´Ù